Therapeutic Programs

therapeutic programs

Pipeline

ProgramStage of Development

Indication

Target

Discovery

Lead Optimization

IND Enabling

Phase 1

Phase 2

Phase 3

Anticipated Milestones

Oncology

Metastatic Castration-Resistant Prostate Cancer

ARV-110AR
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
  • Completed Ph 1 dose escalation data 1H20
Next Generation DegraderAR
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
AR Variant DegraderAR-V7
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3

Metastatic ER+ Breast Cancer

ARV-471ER
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
  • Data in 2H20

Additional Oncology Indications

CRC, NSCLCUndisclosed
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3
Central Nervous System

Tauopathies

MultipleTau
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3

Synucleinopathies

Multipleα-Synuclein
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3

Other neuroscience indications

Unspecified
DiscoveryLead OptimizationIND-EnablingPhase 1Phase 2Phase 3